About Us

Overview

• Our Mission
  Become a world-class RNAi biopharmaceutical innovator and serve patients in need worldwide

  
• Our Vision
  Realize full potential of RNAi technology
  Bring life-changing RNA medicines to reality

  

Leadership Team

• 
  Weimin Wang, Ph.D.

  

  Founder, Chief Executive Officer

  Dr. Weimin Wang is one of the industry's leading oligonucleotide chemists with nearly 30 years of research experience in the field. Dr. Wang has been a key contributor to the RNA therapeutic industry for over 20 years, with more than 60 scientific publications and patents related to RNAi therapeutics. Before founding SanegeneBio, he served as the Executive Director of Chemistry at Dicerna Pharmaceuticals (acquired by Novo Nordisk in 2021) where his team played a crucial role in developing Dicerna's liver-targeting GalXC technology, along with extrahepatic delivery platforms. Prior to joining Dicerna, Dr. Wang was part of Merck & Co. through its acquisition of Sirna, where he developed one of the first lipid nanoparticle delivery systems for nucleic acid therapeutics. Throughout his tenure at Sirna, Merck, and Dicerna, Dr. Wang demonstrated his extensive expertise by evaluating over 500 external opportunities for nucleic acid drug discovery and delivery technology, as well as managing numerous significant partnership collaborations including Eli Lilly, Roche, Novo Nordisk, Boehringer Ingelheim, Alexion, etc.

• 
  Shiyu Wang, Ph.D.

  

  Co-Founder, Chief Scientific Officer

  Dr. Shiyu Wang received her Ph.D. in biochemistry from Penn State University. She has extensive experience in siRNA and antisense therapeutic development under industrial settings. Dr. Wang brings in her unmatched industrial experience in molecular mechanism of therapeutic oligonucleotide delivery, disease-causing genes identification, lead optimization, in vitro/in vivo pharmacology and assay development as well as hepatic/extrahepatic platform discovery. During her tenure at the Ionis Pharmaceutical Core Research Department and Dicerna Pharmaceuticals, Dr. Wang spearheaded numerous key preclinical studies using various disease models, had led multidisciplinary teams advancing internal and external programs from target identification through late-stage development. Dr. Wang had managed numerous major partnerships including Eli Lilly, Novo Nordisk, etc.

• 
  Marc Abrams, Ph.D.

  

  Chief Technology Officer and Head of US Operations

  Dr. Marc Abrams brings 20 years of leadership experience in oligonucleotide therapeutics and targeted delivery of genetic medicines, most recently as CSO of Carbon Biosciences and SVP of Discovery Research at Dicerna Pharmaceuticals (a Novo Nordisk company). He has also held several roles of increasing responsibility at Merck and Co., Inc., and has served on SanegeneBio's Scientific Advisory Board. 

• 
  Yuyan Jin, Ph.D.

  

  Senior Vice President of Clinical and Non-Clinical Development

  Dr. Jin Yuyan is the head of Clinical and Non-Clinical development. She earned her Ph.D. in Clinical Pharmacology from the University of Pittsburgh, served as a critical path fellow for two years at the US FDA, and completed a one-year global clinical scholar program at Harvard Medical School. Before joining SanegeneBio, Dr. Jin worked at Pfizer's US headquarter and Roche China Innovation Center, where she has led or contributed to preclinical research, clinical development, and regulatory submissions for multiple innovative early and late stage programs. Her expertise spans across neuroscience, oncology, infection, and immunology. Dr. Jin has also contributed to multiple technical guidance documents in China as a member of scientific expert committees. She has published numerous scientific papers in internationally renowned journals as the first author or corresponding author, and serves as a reviewer for several internationally recognized journals, such as 《Clinical Pharmacology and Therapeutics》、《Journal of Clinical Pharmacology》、《British Journal of Clinical Pharmacology》.

• 
  Sibo Jiang, Ph.D.

  

  Vice President of CMC

  Dr. Sibo Jiang has 15 years of experience in oligonucleotide synthesis and downstream processing, with a primary focus on oligonucleotide drug substance development and manufacturing. Prior to joining SanegeneBio, Dr. Jiang has held leadership positions at the global leading oligonucleotide leading CDMO, Nitto Denko Avecia. Under Dr. Jiang' s leadership, his therapeutic oligonucleotide team had completed over 70 development and production projects, supporting programs through preclinical, to clinical and pre-commercial stages. Dr. Jiang has extensive therapeutic oligonucleotide industrial experience, especially in the areas of process and analytical platform establishment, method development and optimization, process validation, raw material control, and GLP/GMP scale-up production.

• 
  Yang Liu, M.S., MBA.

  

  Vice President of Business Development

  Yang Liu has nearly 15 years of business development experience in the pharmaceutical industry. He has successfully led or participated in various types of cooperation transactions at different stages and in different fields, including nearly 20 cooperation or transactions such as strategic investment, mergers and acquisitions, product introduction or licensing, joint development, funding research, new business areas and model development, covering multinational pharmaceutical companies, local pharmaceutical companies, biotechnology companies, and university research institutes.

• 
  WEI R. CAMPBELL, J.D.

  

  Vice President of Intellectual Property

  WEI R. CAMPBELL is an intellectual property attorney with over 10 years of experience on a broad range of IP matters in biotechnology, pharmaceuticals, and life sciences, including patent strategy, global patent portfolio development and management, due diligence, IP litigation, transactional matters, trademarks, copyrights, trade secrets, and client counseling. Prior to joining SanegeneBio, she held important positions at biopharmaceutical companies such as Alnylam and BeiGene, leading the development of comprehensive global patent portfolios including oligonucleotide therapies and small molecule drugs, and optimizing global market exclusivity for commercial assets and pipeline programs.

Milestones